Specialist Consultation Conclusion — English Translation

Source (Ukrainian original): docs_eng/2026_new/Oncologist_conclusion_TARGET_clinic_07Aug2026.pdf

Clinic TARGET / "Oncological Clinic Kirkilevsky" LLC, Kyiv, 92-A Povitroflotsky Ave. Medical documentation form No. 028/o.

Consultation details

Referral: Self-referral (no referring institution)

Patient: Zherlitsyna Anastasiia Stanislavivna

Date of birth: 25.04.1976

Consultant: Dr. Kolachko Iryna Volodymyrivna, oncologist

Date of conclusion: 07.08.2026

Lab / imaging results: held by patient ("на руках")

7. Specialist conclusion (disease history summary)

Uterine leiomyosarcoma, T2NxM1, secondary involvement of liver and peritoneum. Status after 4 cycles of chemotherapy per Gemcitabine + Docetaxel + Avastin protocol, with disease progression in the liver (per CT/MRI data, 10/2022). C-KIT, MET mutation detected (ONCOMINE). Status after treatment with Pazopanib (05/12/01/2023) with development of posterior reversible encephalopathy syndrome (PRES) and positive dynamics per CT.

01/2023 — repeat liver biopsy. Pathohistology: metastasis of uterine leiomyosarcoma. Status after 3 cycles of chemotherapy per Trabectedin protocol with negative radiological dynamics (PET/CT dated 11/04/2023). Suspected synchronous gastric neoplasia (GIST?). Status after EUS-FNA gastric biopsy, core biopsy of the liver — histologically confirmed gastrointestinal stromal tumor (GIST) of the stomach, GIST metastasis to the liver (CSD).

08/2023 — status after 4 months of Imatinib treatment with pronounced positive radiological (PET/CT) response.

03/2025 — status after 2 years of Imatinib treatment with positive clinical picture.

05/2025 — stable radiological dynamics on Imatinib therapy.

07/2026 — return of mural (wall) components in known liver lesions on Imatinib therapy after 3.5 years.

Disease progression.

8. Recommendations

Determine PDL, MSI, NTRK, BRAF status — CSD laboratory.

Signature

Oncologist: Kolachko I.V. — 07.08.2026